Publications by authors named "Takehiro Shiraishi"
Article Synopsis
- This study evaluated the effectiveness of comprehensive genomic profiling (CGP) in metastatic colorectal cancer (mCRC) using real-world data from Saitama Medical Center between 2020 and 2023.
- Out of 43 enrolled patients, only 14% received CGP-based therapy, with a median overall survival of 9.7 months for those patients.
- The results indicate that CGP may have potential in guiding treatment for mCRC, as one patient showed a significant response to pembrolizumab after CGP revealed a high tumor mutational burden despite initial classifications.
Article Synopsis
- Tumor budding in colorectal cancer may predict patient outcomes and treatment responses, but it can't be assessed before surgery, limiting its use in treatment planning.
- A study identified high expression of four specific genes (MSLN, SLC4A11, SCEL, and MGAT3) that correlate with tumor budding grades, paving the way for better predictive models.
- A new budding predictive score was developed based on RNA levels from biopsy samples, showing strong potential for preoperative assessments.
Article Synopsis
- The tumor microenvironment, particularly the desmoplastic reaction (DR), significantly influences cancer aggressiveness, with different DR types impacting patient prognosis in colorectal cancer (CRC).
- In a study of 1,497 patients, those with Immature-type DR had the worst relapse-free survival, and cancer-associated fibroblasts (CAFs) from this DR type enhanced tumor growth and spread in experiments.
- High levels of the secreted isoform ADAM9 from CAFs were linked to increased tumor cell proliferation and migration, suggesting a detrimental role in the survival rates of CRC patients with Immature-type DR when ADAM9s was knocked down.
The expression of mesothelin correlates with a poor prognosis in patients with breast cancer. Since mesothelin plays a role in cancer metastasis in association with CA125, we herein examined the expression of mesothelin and CA125, and the clinicopathological meaning and prognosis of the co-expression of mesothelin and CA125 in breast cancer. Our results showed that among 478 patients, mesothelin and CA125 were co-expressed in 48 (10 %), mesothelin only in 75 (16 %), CA125 only in 217 (45 %), and neither in 234 (49 %).
View Article and Find Full Text PDFBackground: Mesothelin (MSLN) is a cell-surface glycoprotein present on mesothelial cells; its expression in several epithelial cancers generally portends an unfavorable prognosis. We investigated MSLN as a surrogate chemopredictive biomarker and examined the impact of MSLN expression in stage IV colorectal cancer (CRC).
Methods: We recruited 254 patients with CRC who received systemic chemotherapy following primary tumor resection between 2000 and 2019.
Article Synopsis
- Mesothelin (MSLN) is a protein found in mesothelial cells, and its high expression in malignant tumors, like stage III colorectal cancer (CRC), indicates a worse prognosis for patients.
- In a study involving 512 stage III CRC patients, 11.9% showed MSLN-positive tumor cells, which correlated with shorter disease-specific survival (DSS) rates, confirming MSLN as a poor prognostic factor.
- MSLN expression remained a significant predictor of poor outcomes even with chemotherapy treatment, suggesting that assessing MSLN in preoperative biopsies could help tailor more intensive chemotherapy for patients with high levels of this marker.
Mesothelin is expressed in various types of malignant tumors. The present study immunohistochemically investigated mesothelin expression and its clinicopathological significance in each subtype of breast cancer, with special reference to its cellular localization, in particular, membrane mesothelin expression. Using tissue specimens from 482 patients with breast cancer, immunohistochemistry was used to study mesothelin expression and help classify its localization as membrane or cytoplasmic expression.
View Article and Find Full Text PDFArticle Synopsis
- Tumor budding is a significant indicator of prognosis in colon cancer (CC), and the study aimed to create a molecular budding signature (MBS) to assess its significance.
- Using frozen tissue samples from 85 colon cancer patients, researchers identified seven genes that contributed to the MBS and measured their expression levels to calculate the MBS score.
- The results showed that a higher MBS score was linked to lower relapse-free survival rates, indicating that the MBS could serve as an independent prognostic marker for determining recurrence risk in colon cancer patients.
5-Fluorouracil (5-FU) is widely used in the treatment of various types of solid cancer. Our study showed that ribosomal protein L11 (RPL11) was a crucial factor affecting sensitivity of gastric cancer to 5-FU, implying that RPL11 expression is a potential biomarker for predicting 5-FU sensitivity. Kaplan-Meier survival analysis indicated that high expression in gastric cancer patients treated with 5-FU was significantly associated with good prognosis.
View Article and Find Full Text PDFMesothelin (MSLN) is a cell surface glycoprotein present in many cancer types. Its expression is generally associated with an unfavorable prognosis. This study examined the prognostic significance of MSLN expression in different areas of individual colorectal cancers (CRCs) using tissue microarrays (TMAs) by enrolling 314 patients with stage II (T3-T4, N0, M0) CRCs.
View Article and Find Full Text PDFBackground: Cancer tissues consist of cancer cells and stroma, the latter of which dictates cancer tissue microenvironment. We recently reported that the desmoplastic reaction (DR) pattern at the invasive front in colorectal cancer (CRC) is a promising prognostic indicator. However, the molecular mechanisms of DR formation and contribution to patients' prognosis remain unclear.
View Article and Find Full Text PDFMesothelin (MSLN) is a cell-surface glycoprotein present on mesothelial cells and in many cancers, where expression is generally associated with an unfavorable prognosis. The clinical significance and pathological characteristics of MSLN expression were evaluated by immunohistochemical staining of tissues from 530 stage ΙΙ/ΙΙΙ colorectal cancer (CRC) patients with R0 resection. Eighty-eight (16.
View Article and Find Full Text PDFWe report an 84-year-old woman with multiple lung metastases from sigmoid colon cancer successfully treated with an oral combination chemotherapeutic agent regimen(UFT/LV).The patient had undergone colectomy for sigmoid colon cancer. Histological examination confirmed a pT4a, pN3, pM1a(LYM), pStage IV tumor.
View Article and Find Full Text PDF